Currently in the midst of a generational transformation of its healthcare system, Egypt has more to recommend it than ever to the global life sciences investment community. Not only is the country attempting to bring its entire 100+ million population under some form of universal health coverage for the first time, but the Egyptian leadership has also rolled out several presidential initiatives tackling key issues including Hepatitis C, chronic disease and kidney failure, and women’s health.
Moreover, Egypt now boasts a revitalized and more robust institutional and regulatory framework, with several new institutions having been created. All this has led to a pharma market which is growing at three times the regional average, stands second only to Saudi Arabia in terms of value within the Middle East & Africa (MEA) region, and takes top spot on volume.
